Evan Zou

Evan Zou is a Senior Analyst at Ally Bridge Group in New York, where he is responsible for the firm’s public equity strategy, with a particular focus on investments in therapeutics and life sciences sectors. In this role, he evaluates innovative biopharmaceutical companies, guiding investment decisions and contributing to portfolio management strategies targeting public healthcare equities.

Prior to joining Ally Bridge Group in 2022, Evan was Associate Director of Portfolio Intelligence at BridgeBio Pharma, where he conducted market and asset diligence across rare disease, oncology, and genetic medicine pipelines. He began his career as an Analyst in Healthcare Investment Banking at Bank of America Securities, building expertise in both capital markets and sector-specific deal analysis.

Evan holds a Bachelor of Science in Economics (Statistics, Finance) from The Wharton School and a Bachelor of Arts in Biophysics from the University of Pennsylvania, graduating summa cum laude. His academic background and professional experience position him as an expert in healthcare, therapeutics, and life sciences public equities.